Literature DB >> 3676929

Experience of the Manitoba Perinatal Screening Program, 1965-85.

J G Fox1.   

Abstract

The Manitoba Perinatal Screening Program is guided by a committee of medical specialists with skills in the diagnosis and management of disorders of metabolism in the newborn. The program is voluntary and is centralized at Cadham Provincial Laboratory, in Winnipeg. A filter card blood specimen is collected from newborns on discharge from hospital, and a filter card urine sample is collected and mailed to the laboratory by the mother when the infant is about 2 weeks of age. The overall compliance rates for the blood and urine specimens are approximately 100% and 84% respectively. The blood specimen is screened for phenylalanine and other amino acids, thyroxine, galactose, galactose-1-phosphate and biotinidase. The urine specimen is screened for amino acids, including cystine, as well as methylmalonic acid and homocystine. Between 1965 and 1985, 83 cases of metabolic disorders were detected, including 23 cases of primary hypothyroidism, 14 of classic phenylketonuria, 5 of galactosemia variants, 3 of galactosemia, 2 of maple syrup urine disease and 1 of hereditary tyrosinemia. The direct cost per infant screened is $5.50, and the cost:benefit ratio is approximately 7.5:1. Maternal serum alpha-fetoprotein screening is being made available as the necessary supporting clinical facilities become available. On the basis of this experience, the author outlines the components that are important for an effective screening program.

Entities:  

Mesh:

Year:  1987        PMID: 3676929      PMCID: PMC1267375     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  6 in total

1.  A SIMPLE CHROMATOGRAPHIC SCREENING TEST FOR THE DETECTION OF DISORDERS OF AMINO ACID METABOLISM. A TECHNIC USING WHOLE BLOOD OR URINE COLLECTED ON FILTER PAPER.

Authors:  M L EFRON; D YOUNG; H W MOSER; R A MACCREADY
Journal:  N Engl J Med       Date:  1964-06-25       Impact factor: 91.245

2.  Maternal serum alpha-fetoprotein screening: report of a Canadian pilot project.

Authors:  T A Doran; G H Valentine; P Y Wong; G Wielgosz; R J Benzie; H C Soltan; M R Jenner; P A Morland; R J Montgomery; L C Allen
Journal:  CMAJ       Date:  1987-08-15       Impact factor: 8.262

3.  Newborn screening for hereditary metabolic disorders in Manitoba, 1965-1970.

Authors:  J G Fox; D L Hall; J C Haworth; A Maniar; L Sekla
Journal:  Can Med Assoc J       Date:  1971-06-19       Impact factor: 8.262

4.  Biotinidase deficiency: the enzymatic defect in late-onset multiple carboxylase deficiency.

Authors:  B Wolf; R E Grier; R J Allen; S I Goodman; C L Kien
Journal:  Clin Chim Acta       Date:  1983-07-15       Impact factor: 3.786

5.  Clinical findings in four children with biotinidase deficiency detected through a statewide neonatal screening program.

Authors:  B Wolf; G S Heard; L G Jefferson; V K Proud; W E Nance; K A Weissbecker
Journal:  N Engl J Med       Date:  1985-07-04       Impact factor: 91.245

6.  Direct solid-phase radioimmunoassay for screening 17 alpha-hydroxyprogesterone in whole-blood samples from newborns.

Authors:  L F Hofman; J E Klaniecki; E K Smith
Journal:  Clin Chem       Date:  1985-07       Impact factor: 8.327

  6 in total
  7 in total

1.  Neonatal screening part 1. General principles.

Authors:  B A Morris
Journal:  Can Fam Physician       Date:  1990-01       Impact factor: 3.275

2.  Neonatal screening part 2: neonatal screening in Canada.

Authors:  B A Morris
Journal:  Can Fam Physician       Date:  1990-02       Impact factor: 3.275

3.  A common mutation associated with the Duarte galactosemia allele.

Authors:  L J Elsas; P P Dembure; S Langley; E M Paulk; L N Hjelm; J Fridovich-Keil
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

4.  Increased prevalence of hereditary metabolic diseases among native Indians in Manitoba and northwestern Ontario.

Authors:  J C Haworth; L A Dilling; L E Seargeant
Journal:  CMAJ       Date:  1991-07-15       Impact factor: 8.262

5.  A molecular approach to galactosemia.

Authors:  L J Elsas; S Langley; E M Paulk; L N Hjelm; P P Dembure
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

6.  Visceral pathology of hereditary tyrosinemia type I.

Authors:  P Russo; S O'Regan
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

7.  Galactosemia: a strategy to identify new biochemical phenotypes and molecular genotypes.

Authors:  L J Elsas; S Langley; E Steele; J Evinger; J L Fridovich-Keil; A Brown; R Singh; P Fernhoff; L N Hjelm; P P Dembure
Journal:  Am J Hum Genet       Date:  1995-03       Impact factor: 11.025

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.